BeOne Medicines Rises 5.11%; Report Estimates RMB78.8844 Million One-Day Gain for 8 Wanjia Funds
2026-10-22 · 3 min read · AlphaGBM
At a glance
According to the report, BeOne Medicines was up 5.11% at RMB275.38 per share as of publication on October 21, with turnover of RMB598 million, a turnover rate of 1.91%, and total market capitalization of RMB424.714 billion. The shares had risen for 4 consecutive days, gaining a cumulative 9.17% over that period. Citing a third-party database, the article said 8 funds managed by Wanjia Fund held a combined 5.8957 million BeOne Medicines shares among their major second-quarter positions. Based on the previous close of RMB262 and the publication-time price of RMB275.38, it estimated a one-day unrealized gain of RMB78.8844 million and a 4-day unrealized gain of RMB130 million. Wanjia Select held 2 million shares in the second quarter, unchanged from the prior period; under the same calculation, its estimated unrealized gains were about RMB26.76 million for the day and RMB44.02 million over 4 days. The company researches, develops, produces and commercializes innovative medicines, with drug sales accounting for 98.10% of operating revenue and collaboration arrangements for 1.90%.
Summary
According to the report, BeOne Medicines was up 5.11% at RMB275.38 per share as of publication on October 21, with turnover of RMB598 million, a turnover rate of 1.91%, and total market capitalization of RMB424.714 billion. The shares had risen for 4 consecutive days, gaining a cumulative 9.17% over that period. Citing a third-party database, the article said 8 funds managed by Wanjia Fund held a combined 5.8957 million BeOne Medicines shares among their major second-quarter positions. Based on the previous close of RMB262 and the publication-time price of RMB275.38, it estimated a one-day unrealized gain of RMB78.8844 million and a 4-day unrealized gain of RMB130 million. Wanjia Select held 2 million shares in the second quarter, unchanged from the prior period; under the same calculation, its estimated unrealized gains were about RMB26.76 million for the day and RMB44.02 million over 4 days. The company researches, develops, produces and commercializes innovative medicines, with drug sales accounting for 98.10% of operating revenue and collaboration arrangements for 1.90%.